Evidence map›Paper›PMID 28899020›Full record

ArticleBrain : a journal of neurology2017

Progression marker of Parkinson's disease: a 4-year multi-site imaging study.

Roxana G Burciu, Edward Ofori, Derek B Archer, Samuel S Wu, Ofer Pasternak, Nikolaus R McFarland, Michael S Okun, David E Vaillancourt

Open access · hybridAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 190 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. One-Year Substantia NigraMovement disorders : official journal of the Movement Disorder Society · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Disease-Modifying Trials in Treated Parkinson's Disease: "Stable Treated" Does Not Equate with Biological Stability.Movement disorders : official journal of the Movement Disorder Society · 2025
    Review

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Roxana G BurciuUniversity of Florida, Department of Applied Physiology and Kinesiology, Gainesville, FL, USA.
Edward OforiUniversity of Florida, Department of Applied Physiology and Kinesiology, Gainesville, FL, USA.
Derek B ArcherUniversity of Florida, Department of Applied Physiology and Kinesiology, Gainesville, FL, USA.
Samuel S WuUniversity of Florida, Department of Biostatistics, Gainesville, FL, USA.
Ofer PasternakHarvard Medical School Departments of Psychiatry and Radiology, Brigham and Women's Hospital, Boston, MA, USA.
Nikolaus R McFarlandUniversity of Florida, Department of Neurology, Gainesville, FL, USA.
Michael S OkunUniversity of Florida, Department of Neurology, Gainesville, FL, USA.
David E VaillancourtUniversity of Florida, Department of Applied Physiology and Kinesiology, Gainesville, FL, USA.
University of Florida · USHarvard University · US

Funding

Using social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2M
University of Florida Older Americans Independence Center (OAIC)P30AG028740 · NIA · UNIVERSITY OF FLORIDA · PI CHRISTIAAN LEEUWENBURGH · 2007 to 2026
$22.8M
Training and DisseminationP41EB015902 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI KIKINIS, RON, WESTIN, CARL-FREDRIK · 2012 to 2022
$20.9M
Scaling and Sequencing Motor Output in Humans: fMRI StudyR01NS052318 · NINDS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI VAILLANCOURT, DAVID E · 2005 to 2020
$6.0M
Interdisciplinary Training in Movement Disorders and NeurorestorationT32NS082168 · NINDS · UNIVERSITY OF FLORIDA · PI Melissa Jo Armstrong, David E Vaillancourt · 2015 to 2026
$2.8M
Next Generation Diffusion MRI Biomarkers for Prodromal SchizophreniaR01MH108574 · NIMH · BRIGHAM AND WOMEN'S HOSPITAL · PI PASTERNAK, OFER · 2016 to 2020
$2.2M
NCATS NIH HHS UL1 TR001427NIA NIH HHS P30 AG028740NIBIB NIH HHS P41 EB015902NIMH NIH HHS R01 MH108574NINDS NIH HHS R01 NS052318NINDS NIH HHS T32 NS082168
6 · The paper itself

Abstract

Progression markers of Parkinson's disease are crucial for successful therapeutic development. Recently, a diffusion magnetic resonance imaging analysis technique using a bitensor model was introduced allowing the estimation of the fractional volume of free water within a voxel, which is expected to increase in neurodegenerative disorders such as Parkinson's disease. Prior work demonstrated that free water in the posterior substantia nigra was elevated in Parkinson's disease compared to controls across single- and multi-site cohorts, and increased over 1 year in Parkinson's disease but not in controls at a single site. Here, the goal was to validate free water in the posterior substantia nigra as a progression marker in Parkinson's disease, and describe the pattern of progression of free water in patients with a 4-year follow-up tested in a multicentre international longitudinal study of de novo Parkinson's disease (http://www.ppmi-info.org/). The analyses examined: (i) 1-year changes in free water in 103 de novo patients with Parkinson's disease and 49 controls; (ii) 2- and 4-year changes in free water in a subset of 46 patients with Parkinson's disease imaged at baseline, 12, 24, and 48 months; (iii) whether 1- and 2-year changes in free water predict 4-year changes in the Hoehn and Yahr scale; and (iv) the relationship between 4-year changes in free water and striatal binding ratio in a subgroup of Parkinson's disease who had undergone both diffusion and dopamine transporter imaging. Results demonstrated that: (i) free water level in the posterior substantia nigra increased over 1 year in de novo Parkinson's disease but not in controls; (ii) free water kept increasing over 4 years in Parkinson's disease; (iii) sex and baseline free water predicted 4-year changes in free water; (iv) free water increases over 1 and 2 years were related to worsening on the Hoehn and Yahr scale over 4 years; and (v) the 4-year increase in free water was associated with the 4-year decrease in striatal binding ratio in the putamen. Importantly, all longitudinal results were consistent across sites. In summary, this study demonstrates an increase over 1 year in free water in the posterior substantia nigra in a large cohort of de novo patients with Parkinson's disease from a multi-site cohort study and no change in healthy controls, and further demonstrates an increase of free water in Parkinson's disease over the course of 4 years. A key finding was that results are consistent across sites and the 1-year and 2-year increase in free water in the posterior substantia nigra predicts subsequent long-term progression on the Hoehn and Yahr staging system. Collectively, these findings demonstrate that free water in the posterior substantia nigra is a valid, progression imaging marker of Parkinson's disease, which may be used in clinical trials of disease-modifying therapies.

Indexed as

Disease ProgressionBiomarkersCase-Control StudiesCorpus StriatumDiffusion Magnetic Resonance ImagingDopamine Plasma Membrane Transport ProteinsFemaleHumansLongitudinal StudiesMaleMiddle AgedNeuroimagingParkinson DiseaseSubstantia NigraWaterBiomarkersDopamine Plasma Membrane Transport ProteinsWaterbasal gangliabiomarkersfree waterimagingParkinson’s disease

Identifiers

PMID28899020
PMCPMC6057495
OpenAlexW2737145049

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.